Human skin replacement - Clinical Cell Culture

Drug Profile

Human skin replacement - Clinical Cell Culture

Alternative Names: CellSpray; CellSpray XP

Latest Information Update: 04 May 2005

Price : $50

At a glance

  • Originator Clinical Cell Culture
  • Class Cell therapies
  • Mechanism of Action Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Marketed Burns

Most Recent Events

  • 09 Sep 2003 Preregistration for Burns in Belgium (Topical)
  • 09 Sep 2003 Clinical Cell Culture has filed a marketing approval application with the Belgium Ministry of Health for Burns
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top